Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
PRLD 
Prelude Therapeutics Inc (PRLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/23/2025: PRLD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.64% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 137.67M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 4 | Beta 1.06 | 52 Weeks Range 0.61 - 4.22 | Updated Date 12/24/2025 |
52 Weeks Range 0.61 - 4.22 | Updated Date 12/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.47 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -314.12% |
Management Effectiveness
Return on Assets (TTM) -51.82% | Return on Equity (TTM) -103.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26205495 | Price to Sales(TTM) 13.11 |
Enterprise Value 26205495 | Price to Sales(TTM) 13.11 | ||
Enterprise Value to Revenue 9.58 | Enterprise Value to EBITDA -0.54 | Shares Outstanding 50015011 | Shares Floating 16354247 |
Shares Outstanding 50015011 | Shares Floating 16354247 | ||
Percent Insiders 9.93 | Percent Institutions 54.48 |
Upturn AI SWOT
Prelude Therapeutics Inc
Company Overview
History and Background
Prelude Therapeutics Inc. was founded in 2011 and is a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for hematological malignancies and solid tumors. The company has a pipeline of targeted therapies designed to address the underlying drivers of cancer. Key milestones include the initiation of clinical trials for its lead drug candidates and strategic partnerships.
Core Business Areas
- Drug Discovery and Development: Prelude Therapeutics focuses on developing novel small molecule inhibitors targeting key signaling pathways implicated in cancer, aiming to create more effective and less toxic therapies.
Leadership and Structure
Prelude Therapeutics is led by a management team with extensive experience in drug development and the biopharmaceutical industry. The company operates with a lean, research-intensive structure, with a focus on advancing its pipeline through clinical development.
Top Products and Market Share
Key Offerings
- PRT562: A potent and selective inhibitor of the PI3K delta (PI3Ku03b4) and PI3K gamma (PI3Ku03b3) isoforms. It is being investigated for the treatment of hematological malignancies. Competitors include companies developing other PI3K inhibitors such as Gilead Sciences (Zydelig) and TG Therapeutics (umbralisib).
- PRT1419: A potent and selective inhibitor of mTORC1 and mTORC2. It is being investigated for the treatment of hematological malignancies and solid tumors. Competitors include companies developing mTOR inhibitors such as Novartis (everolimus) and Pfizer (temsirolimus).
- PRT2721: A potent and selective inhibitor of the FLT3 and KIT kinases. It is being investigated for the treatment of acute myeloid leukemia (AML) and other hematological malignancies. Competitors include companies developing FLT3 inhibitors such as Astellas Pharma (gilteritinib) and Pfizer (midostaurin).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in oncology, is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. There is a continuous demand for novel therapies with improved efficacy and safety profiles for cancer patients. The market is competitive, with both large pharmaceutical companies and smaller biotech firms vying for market share.
Positioning
Prelude Therapeutics is positioned as an emerging player in the oncology drug development space, focusing on targeted therapies. Its competitive advantages lie in its differentiated pipeline of novel drug candidates targeting key oncogenic pathways.
Total Addressable Market (TAM)
The total addressable market for hematological malignancies and solid tumors is substantial, running into hundreds of billions of dollars globally. Prelude Therapeutics is positioned to address a segment of this market with its specialized pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform.
- Pipeline of novel, targeted therapies.
- Experienced management team.
- Focus on high unmet medical needs in oncology.
Weaknesses
- Clinical-stage company with no approved products yet.
- Reliance on future clinical success and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
- Execution risk in drug development and commercialization.
Opportunities
- Unmet medical needs in hematological malignancies and solid tumors.
- Advancements in understanding cancer biology.
- Potential for strategic partnerships and collaborations.
- Growing demand for targeted cancer therapies.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Intense competition from established and emerging companies.
- Pricing and reimbursement challenges.
- Patent expirations of existing therapies.
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- Novartis AG (NVS)
- Pfizer Inc. (PFE)
- Astellas Pharma Inc. (ASTLF)
- TG Therapeutics, Inc. (TGTX)
Competitive Landscape
Prelude Therapeutics faces competition from established pharmaceutical giants and other biotech firms. Its advantage lies in developing novel, highly specific inhibitors, potentially offering differentiated therapeutic profiles. However, competitors have larger resources, established sales forces, and broader portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Prelude Therapeutics has been characterized by pipeline expansion, advancement of drug candidates into clinical trials, and equity financing rounds to fund these activities.
Future Projections: Future growth projections are heavily dependent on the successful completion of clinical trials, regulatory approvals, and eventual commercialization of its drug candidates. Analyst estimates would focus on potential peak sales of pipeline assets and the overall market opportunity.
Recent Initiatives: Recent initiatives likely include the initiation and progression of clinical trials for its lead drug candidates (e.g., PRT562, PRT1419, PRT2721), potential licensing or collaboration agreements, and ongoing research to expand its pipeline.
Summary
Prelude Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline of targeted oncology therapies. Its strengths lie in its innovative drug discovery platform and focus on high unmet needs. However, it faces significant risks associated with clinical development, regulatory approval, and intense competition. The company's future success hinges on successful clinical trial outcomes and its ability to secure adequate funding for its ambitious development programs.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Websites
- SEC Filings (10-K, 10-Q)
- Financial News and Analysis Platforms (e.g., Yahoo Finance, Bloomberg)
- Industry Research Reports
Disclaimers:
This information is for informational purposes only and does not constitute investment advice. Financial data and market share information are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prelude Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2020-09-25 | Founder, CEO & Director Dr. Krishna Vaddi D.V.M., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://preludetx.com |
Full time employees 131 | Website https://preludetx.com | ||
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.